Northbaze Group AB will receive approximately SEK 5.
Redeye comments on Ortoma’s announcement yesterday that they have submitted a supplemental 510(k) to...
Redeye comments on CLS’s recap of 2024 and outlook for 2025-2026.
Redeye briefly comments on Physitrack’s announcement to streamline its subsidiary, Champion Health, ...
Ahead of Elanders' Q4 report, we lower 2024E adjusted EBITA by 2%, while we raise 2025E-26E by 2%.
Redeye comments on Iconovo’s collaboration with Lonza to develop a reformulated obesity treatment.
Redeye comments on Arise’s new SEK50m share repurchase program, refinancing its green facility of EU...
Redeye leaves a comment following Klaria’s recent announcement of a licensing agreement with CNX The...
Henrik Andersson, who has served as CEO of Northbaze since 2018, has informed the board of directors...
Redeye makes minor revisions to estimates ahead of Enea’s Q4 2024 report due on 30 January 2025.
Taaleri announced today 9 January, that its CEO Peter Ramsay has resigned and will leave his positio...
Redeye provides a comment on Xspray following yesterday's press release announcing a delay in the re...
Duell publishes its Q1/2025 (9/24-11/24) business review on 16th of January.
Q4 report due 11 February We forecast Q4 net sales of SEK 520m & EBITA of SEK 78m We reiterate our f...
Redeye comments on Sivers Semiconductors’ announcement of a new USD5.
